{
  "report_rows": [
    {
      "kpi": "Q2 adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.48 vs. cons $1.43",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 net sales",
      "prediction": "IN-LINE",
      "answer": "pred ~$2.64B vs. cons $2.634B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 adjusted gross margin",
      "prediction": "IN-LINE",
      "answer": "pred ~41.4% vs. cons 41.0%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "LOWER",
      "answer": "guide ~$8.45 vs. cons $8.48 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Reported net sales growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~4.75% vs. cons 4.73% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EPS growth commentary",
      "prediction": "LOWER",
      "answer": "guide ~15.0% vs. cons 16.7% (FY2027)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -2.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -3.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A modest Q2 EPS beat is outweighed by an FY2026 guide midpoint below consensus and FY2027 commentary that does not validate the full Street recovery. Using predicted H1 adjusted EPS of ~$3.83, the ~$8.45 FY2026 guide implies ~$4.62 for H2 versus consensus near $4.67, prompting modest out-period estimate cuts after the initial reaction.",
  "day5_confidence": "MEDIUM"
}